Skip to main content
Equibles
IONS logo

IONS · Ionis Pharmaceuticals Inc · Metrics

Track IONS — free

Use IONS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IONS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$44.88 +0.50 (+1.13%)
Russell 1000 member Rebalance outlook locked
Market Cap
$7.38B
Shares
166.18M
Volume · Oct 20 287.08K Avg daily vol (3M) 3.27M

IONS metrics

80 of 116 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$44.38
Market cap
$7.38B

Price action

20 metrics
Price change (1W)
+1.6%
Price change (30D)
-1.2%
Price change (3M)
-16.2%
Price change (6M)
-40.7%
Price change (YTD)
-43.9%
Price change (1Y)
-39.3%
Trailing year
Price change (5Y)
+41.9%
52-week high
$86.50
52-week low
$42.38
Change from 52-week high
-48.7%
Change from 52-week low
+4.7%
Annualized volatility
42.7%
Annualized volatility (3M)
43.7%
Beta
0.5
RSI (14D)
43.5
Price vs SMA 50
-13.8%
Price vs SMA 200
-35.1%
Avg volume (3M)
3.27M
Relative volume
1.0
Average dollar volume
$167.45M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
166.18M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
7.1×
reciprocal yield 14.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
8.2×
reciprocal yield 12.2%
P / book
16.2
reciprocal yield 6.2%
FCF yield
-7.9%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.9%

Historical valuation

8 metrics
P / E historical average (3Y)
60.3×
reciprocal yield 1.7%
P / E historical average (5Y)
60.3×
reciprocal yield 1.7%
EV / revenue historical average (3Y)
8.1×
reciprocal yield 12.4%
EV / revenue historical average (5Y)
8.0×
reciprocal yield 12.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
98.2%
Operating margin
-68.0%
Trailing 12 months
Net margin
-64.7%
Gross profit (TTM)
$858.07M
Operating profit (TTM)
−$594.36M
Net income (TTM)
−$565.17M
Trailing 12 months
Diluted EPS (TTM)
$-3.46
FCF margin
-64.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.57
Stock compensation per diluted share (TTM)
—
Book value per share
$2.99

Growth

11 metrics
Revenue growth YoY
-40.7%
Year over year
Net income growth YoY
-192.8%
Revenue (TTM)
$874.09M
Trailing 12 months
EPS growth YoY
-198.6%
Shares change YoY
-9.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+17.1%
Revenue CAGR (5Y)
+5.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-128.5%
Return on assets
-18.9%
Debt / equity
3.6
Current ratio
7.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$560.84M
Quick ratio
7.7
Interest coverage
-31.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$917.32M
Latest balance sheet
Cash & equivalents
$350.06M
Total assets
$2.99B
Total debt
$1.76B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$496.43M
Capital expenditures (TTM)
$64.41M
R&D (TTM)
$173.70M
SG&A (TTM)
$527.75M
Stock compensation (TTM)
$163.34M
R&D / revenue
—
Stock compensation / revenue
18.7%

Ownership (13F)

3 metrics
13F filers
523
13F filer change QoQ
+21
Institutional ownership
112.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.9%

Short interest

3 metrics
Short interest
13.5%
Latest settlement · 4.6 days to cover
Days to cover
4.6d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
$997,311
Insider-sentiment score
73 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 874015 CUSIP 462222100 13F (30d) 41 filings 40 filers Visit website Investor relations